Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tiny Mabion Races Big Pharma To EU Rituximab Market

Executive Summary

Poland’s biotech Mabion is racing to the European biosimilar market with a biosimilar rituximab, but is up against multinational biosimilar companies like Sandoz and South Korea’s Celltrion, and will likely need a strong commercialization partner outside its home market.

You may also be interested in...



Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval

Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.

Celltrion’s Biosimilar Rituximab Edges Ahead With Korean Approval

Celltrion has edged ahead of its competitors in the close race to develop biosimilar versions of rituximab with the approval of its product in South Korea, which could help speed development in other markets where the South Korean firm is also seeking approvals.

Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon

Verastem steps in where AbbVie exited, agreeing to license Infinity’s duvelisib in hematologic cancer indications. Celldex grows its immuno-oncology pipeline with buyout of private Yale Medical School-spinout Kolltan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel